Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 251

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 251
---
 A SPAC I Mini Acquisition Corp., Merger Sub, NewGenIvf Limited,
a Cayman Islands exempted company (“Legacy NewGenIvf”) and certain shareholders of Legacy NewGenIvf. Pursuant to the Merger
Agreement, the Business Combination was effected in two steps: (i) ASCA was reincorporated to the British Virgin Islands by merging with
and into A SPAC I Mini Acquisition Corp. (such transaction, the “Reincorporation Merger”) and then the listed company was
renamed as NewGenIvf Group Limited; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a
wholly-owned subsidiary of the Company (such second step in isolation, the “Acquisition Merger”). The surviving entity of
the Business Combination, together with its subsidiaries is referred to in this prospectus as “NewGenIvf,” the “Company,”
“we,” “our,” or “us,” unless the context otherwise requires.

On June 12, 2023, the parties
to the Merger Agreement entered into the First Amendment to Merger Agreement (the “First Amendment”), pursuant to which Legacy
NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the “Loan”) to
ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA’s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from Legacy NewGenIvf, ASCA
agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf’s failure to deliver audited
financial statements by no later than February 28, 2023.

On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the “Second Amendment”) which
amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf’s board of directors following
the consum